CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed
Drug / intervention
Valproic Aciddrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00374075
NCT00374075Phase 1Completed
CompareCT.gov

In Vivo Study of Safety, Tolerability and Dosing Effect on SMN mRNA and Protein Levels of Valproic Acid in Patients With Spinal Muscular Atrophy

University of Utah·interventional·Posted Sep 8, 2006·Updated May 10, 2023

In Brief

A Phase 1 clinical trial evaluating Valproic Acid for Spinal Muscular Atrophy. Completed, across 1 site.

Detailed Summary

This is an open label phase I/II clinical trial to assess safety, tolerability and potential effect on SMN mRNA and protein in vivo of a compound in which preliminary evidence supports a potential effect on SMN levels in vitro.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSpinal Muscular Atrophy
CountriesUnited States
CollaboratorsFamilies of Spinal Muscular Atrophy, Leadiant Biosciences, Inc., Abbott

Timeline

Phase 1CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 8, 2006
Enrollment StartSep 1, 2003
Study CompletionFeb 1, 2006
TodayJul 2, 2026
Posted 19.8 years ago

Interventions

Valproic Aciddrug